Lannett (LCI) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
August 24, 2022 4:15 PM EDTQ4 Business and Financial Highlights:
Net Sales were $74.2 MillionAdjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30Completed Major Elements of November 2021 Restructuring PlanPipeline Updates:
Pivotal Biosimilar Insulin Glargine Clinical Trial Over 90% Complete, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023Expect to File IND for Biosimilar Insulin Aspart by First Half of 2023Generic FLOVENT®... More